Diabetic Foot Ulcers Pipeline Therapeutics Development Review H2 2015

Press Release   •   Jan 13, 2016 08:43 EST

This report provides comprehensive information on the therapeutic development for Diabetic Foot Ulcers, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Foot Ulcers and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Diabetic Foot Ulcers” addition with 49 market data tables and 15 figures, spread across 149 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Adocia, Aprogen, Inc., Bayer AG, CardioVascular BioTherapeutics, Inc., Celgene Corporation, CoDa Therapeutics, Inc., CytoTools AG, Dipexium Pharmaceuticals LLC, EyeGene, Inc., FirstString Research, Inc., GlaxoSmithKline Plc, Human Stem Cells Institute, Innovaxis, Izun Pharmaceuticals Corporation, Karyopharm Therapeutics, Inc., Lytix Biopharma AS, MediaPharma s.r.l., MediWound Ltd., NovaLead Pharma Pvt. Ltd., Oneness Biotech Co., Ltd., Osiris Therapeutics, Inc., Plurogen Therapeutics, Inc., Sanofi, Stratatech Corporation, TechnoPhage SA, TGV-Laboratories, Theravasc, Inc., Tissue Med Biosciences and USV Limited

Drugs Profile Discussed in this Research:

ALLO-ASC, AP-102, APO-2, becaplermin, Biochaperone PDGF-BB, Cell Therapy to Activate Cathelicidin for Diabetic Foot Ulcers and Crural ulcer, Cell Therapy to Activate VEGF for Venous Leg Ulcers and Diabetic Foot Ulcers, CL-05, CODA-001, CVBT-141B, Cyndacel-M, daprodustat, Drug for Diabetic Foot Ulcer, EG-Decorin, epidermal growth factor biosimilar, EscharEx, esmolol hydrochloride, Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers, Granexin, Heberprot-P, IMSP-001, IZN-6D4, LTX-109, MPHE-001A, MT-003, Mul-1867, Neovasculgen, Nu-2, Nu-3, ON-101, OTI-1501, PDA-002, pexiganan acetatePluroGel N, Recombinant Erythropoetin for Wounds, Bone Regeneration and Diabetic Ulcers, selinexor, sodium nitrite SR, Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds, TMBP-3, TP-102 and Vivefoot

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Diabetic Foot Ulcers
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Foot Ulcers and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Foot Ulcers products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Foot Ulcers pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Foot Ulcers
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Foot Ulcers pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Diabetes Therapeutics Market. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries